Tumor Debulking Adds Toxicity Without Survival Benefit in Metastatic Colorectal Cancer

The Creep of Local Therapy in Metastatic Colorectal Cancer

Local treatment of metastases is the standard of care for selected patients with oligometastatic colorectal cancer, and this approach is increasingly being applied to patients with more extensive, multiorgan metastatic disease [1, 2]. The theoretical goal of adding surgery, radiation, or thermal ablation to palliative systemic therapy is to extend overall survival by maximizing tumor clearance. However, these local interventions carry a risk of serious adverse events that could negatively impact a patient's health-related quality of life during palliative care [2, 3]. Because definitive prospective data have been lacking, multidisciplinary teams often face difficult decisions regarding how aggressively to pursue tumor debulking in patients with widespread disease [1]. A newly published randomized clinical trial now provides clear evidence on whether this aggressive local approach actually translates to a survival benefit, offering critical guidance for oncologists weighing the risks of surgical morbidity against the hope of extending life.

Defining the Threshold for Aggressive Local Therapy

To evaluate the utility of aggressive local interventions, researchers conducted an investigator-initiated, open-label, multicenter, randomized clinical trial (identifier NCT01792934). Between May 2013 and May 2023, the study enrolled adult patients with multiorgan metastatic colorectal cancer across 27 hospitals in the Netherlands and one hospital in the UK. The investigators established strict eligibility criteria to ensure that local therapy was technically viable. Specifically, patients were only considered eligible if multidisciplinary teams determined that more than 80 percent tumor debulking was feasible using resection, radiotherapy, and/or thermal ablation prior to the initiation of first-line palliative chemotherapy.

Before proceeding to local therapy, all eligible patients underwent a mandatory period of induction systemic treatment. Participants received either three cycles of capecitabine and oxaliplatin or four cycles of 5-fluorouracil and oxaliplatin, with or without the addition of bevacizumab. Only patients who achieved an objective tumor response or stable disease following this initial chemotherapy were subsequently randomized in a 1:1 ratio. Following randomization, participants were assigned to receive either chemotherapy alone (the standard care group) or tumor debulking followed by continued chemotherapy.

The investigators designed the trial with a primary end point of overall survival to definitively test whether the addition of local therapy extended life. Secondary end points included progression-free survival and serious adverse events, providing a comprehensive view of the treatment's risk-to-benefit profile. All outcomes were analyzed in the intention-to-treat population (a standard statistical approach that analyzes patients according to their randomized group regardless of the treatment they actually received), which was applicable from the point of randomization. Furthermore, a prespecified interim analysis was performed after the initial 100 participants were enrolled. This early evaluation revealed that the trial was both safe and feasible to proceed, allowing the researchers to complete the decade-long enrollment phase.

Cohort Characteristics and Randomization Flow

Following the initial induction phase to confirm disease stability or response, the investigators proceeded with treatment assignment. Ultimately, a total of 382 of 454 enrolled patients were randomized to one of the two study arms. The attrition from the initial enrollment number reflects those who did not meet the strict criteria of objective tumor response or stable disease after their initial cycles of systemic therapy. By ensuring that only patients with controlled disease proceeded to the comparative phase of the trial, the researchers selected for a patient population whose tumor biology was already somewhat favorable, making the test of local therapy even more rigorous.

The randomization process yielded two well-matched cohorts for the intention-to-treat analysis. In the standard care arm, 192 patients were in the chemotherapy alone group, a cohort that included 133 male patients (69 percent). The experimental arm was nearly identical in size, with 190 patients in the chemotherapy plus tumor debulking group, which included 127 male patients (67 percent). Baseline demographic characteristics were evenly distributed across the trial, as the median age was 64 years in both groups. This balanced distribution ensures that any subsequent differences in survival or toxicity can be reliably attributed to the addition of local therapy rather than underlying demographic variations.

Survival Outcomes and Increased Toxicity

The trial concluded with the last date of follow-up on April 4, 2024. After a median follow-up of 32.3 months, the addition of local therapy did not yield a statistically significant survival benefit. The researchers reported that the median overall survival in the chemotherapy alone group was 27.5 months vs 30.0 months in the chemotherapy plus tumor debulking group (adjusted hazard ratio, 0.88 [95% CI, 0.70-1.10]; P = .26). Similarly, disease progression timelines were nearly identical between the two cohorts. The median progression-free survival in the chemotherapy alone group was 10.4 months vs 10.5 months in the chemotherapy plus tumor debulking group (adjusted hazard ratio, 0.83 [95% CI, 0.67-1.02]; P = .08).

While survival outcomes remained unchanged, the aggressive local intervention carried a substantial cost in terms of toxicity. The data showed that more patients in the chemotherapy plus tumor debulking vs chemotherapy alone group had any serious adverse events (101 [53%] vs 74 [39%]; P = .006). Based on these definitive results, the investigators concluded that tumor debulking in addition to first-line palliative systemic treatment failed to improve overall survival compared with systemic treatment alone for patients with multiorgan metastatic colorectal cancer. For practicing oncologists, these findings provide a clear mandate to prioritize quality of life and systemic control. Because this approach adds significant morbidity without extending life, the authors state that tumor debulking in addition to first-line palliative systemic treatment should not be considered standard care.

References

1. Bakkerus L, Gootjes E, Stok EP, et al. The ORCHESTRA trial; A phase III trial of adding tumour debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC). Annals of Oncology. 2019. doi:10.1093/annonc/mdz246.146

2. Gootjes EC, Stok EPVD, Buffart TE, et al. Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer.. The oncologist. 2020. doi:10.1634/theoncologist.2019-0693

3. Bakkerus L, Buffart LM, Buffart TE, et al. Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking.. Journal of the National Comprehensive Cancer Network : JNCCN. 2023. doi:10.6004/jnccn.2023.7050